FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Cytokine topics
Antibodies
Inflammation
Specificity
Immunotherapy
Major Histocompatibility Complex
Compatibility
Combination Therapy
Histocompatibility
Immune Response
Monoclonal Antibody
Stimulator
Therapeutics
Immunostimulator
Monoclonal
Proinflammatory

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Cytokine patents



      
           
This page is updated frequently with new Cytokine-related patent applications. Subscribe to the Cytokine RSS feed to automatically get the update: related Cytokine RSS feeds. RSS updates for this page: Cytokine RSS RSS


Date/App# patent app List of recent Cytokine-related patents
11/13/14
20140336220
 Composition for preventing or treating obesity comprising rebamipide patent thumbnailComposition for preventing or treating obesity comprising rebamipide
The present disclosure relates to a composition and a health functional food for preventing or treating obesity comprising a rebamipide compound or its pharmaceutically acceptable salt as an active component. It is confirmed that when a rebamipide compound of the present disclosure is administered to a mouse model induced with obesity, it shows excellent effects of reducing weight, reducing adipocyte, and reducing a total cholesterol content in the body, as compared with a non-administered control group, and also, it shows an excellent effect of suppressing differentiation of cytotoxic th17 cells that generate and secrets inflammatory cytokine and an excellent effect of improving activity of regulatory t cells (treg) capable of suppressing a function of abnormally activated immune cells and controlling an inflammatory reaction.
11/13/14
20140336076
 Method for diagnosing and treating fibromyalgia patent thumbnailMethod for diagnosing and treating fibromyalgia
The invention provides methods, kits and reagents for diagnosing fibromyalgia (fm) in an individual by determining whether the levels of one or more cytokines in the individual are altered, as compared to control levels. The altered level(s) or patterns of expression of the cytokines measured in the affected individual compared to the level from the control is predictive/indicative of fm in the.
11/13/14
20140335108
 Utility of insulin-like 6 (insl6) for the treatment of autoimmune diseases patent thumbnailUtility of insulin-like 6 (insl6) for the treatment of autoimmune diseases
The present invention is directed to compositions and methods to treat an autoimmune disease in a subject, comprising an insulin-like 6 (insl6) agent, such as an insl6 polypeptide or variant or fragment thereof, or a nucleic acid encoding insl6 poly peptide or variant or fragment thereof. Aspects of the present invention relate to use of insl6 agents to reduce t-regulatory (treg) cells in the subject and to reduce pro-inflammatory cytokines in a subject with an autoimmune disease such as a muscle autoimmune disease.
11/13/14
20140335103
 Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof patent thumbnailCytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof
The disclosure relates to methods and compositions effective in the diagnosis, prognosis and treatment of human hematopoietic cancers. In particular, the disclosure provides tumor-associated genes that encode for cytokine receptors that are differentially expressed in hematopoietic tumor cells of myeloid origin compared with other cells, e.g., normal stem cells..
11/13/14
20140335094
 Mammalian cytokines; related reagents and methods patent thumbnailMammalian cytokines; related reagents and methods
Purified genes encoding cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided..
11/06/14
20140330349
 Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation patent thumbnailExtremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
Described herein are systems and methods for applying extremely low duty-cycle stimulation sufficient to treat chronic inflammation with progressively longer delays (off periods) from an initial stimulation. In particular, described herein are supra-threshold pulses of electrical stimulation sufficient to result in a long-lasting (e.g., >48 hours) inhibition of pro-inflammatory cytokines and/or effects of chronic inflammation; the delay between initial doses (which may be single-pulse doses) may be extended for subsequent doses, potentially dramatically enhancing battery and device longevity..
11/06/14
20140329721
 Assay panels patent thumbnailAssay panels
Described herein are kits and components thereof used for a multiplexed analysis of a set of cytokines.. .
11/06/14
20140328798
 Co-administration of a parvovirus and a cytokine for therapy of pancreatic cancer patent thumbnailCo-administration of a parvovirus and a cytokine for therapy of pancreatic cancer
The present invention relates to a combination of a parvovirus and a cytokine, preferably ifnγ, for use in treating pancreatic cancer, in particular a terminal stage of this disease.. .
10/30/14
20140323731
 Lipidated imidazoquinoline derivatives patent thumbnailLipidated imidazoquinoline derivatives
The compounds of the subject invention are adjuvant molecules that comprise an imidazoquinoline molecule covalently linked to a phospho- or phosphonolipid group. The compounds of the invention have been shown to be inducers of interferon-a, il-12 and other immunostimulatory cytokines and possess an improved activity profile in comparison to known cytokine inducers when used as adjuvants for vaccine antigens..
10/30/14
20140323401
 Tissue protective peptides and uses thereof patent thumbnailTissue protective peptides and uses thereof
The present invention is directed to novel tissue protective peptides. The tissue protective peptides of the invention may bind to a tissue protective receptor complex.
10/30/14
20140323355
Urinary biomarkers for cancer diagnosis
The present invention is directed to the field of cancer diagnosis, specifically to the diagnosis of bladder cancer (bc) and prostate cancer (cap). More specifically, the invention provides simple, non-invasive urinary tests characterized by high sensitivity and specificity, wherein urinary levels of heat shock proteins and anti-inflammatory cytokines are used as biomarkers..
10/30/14
20140322266
Induction of mucosal tolerance to antigens
The present invention relates to the induction of tolerance to antigens, by mucosal, preferably oral delivery of the antigen in combination with an immunomodulating compound producing micro-organism. More specifically, the invention relates to the induction of foxp3+ and/or il-10 and/or tgf-β producing regulatory t-cells, capable of suppressing undesired immune responses toward an antigen, by oral delivery of said antigen in combination with an immunosuppressing cytokine secreting micro-organism..
10/30/14
20140322249
Dna vaccines against tumor growth and methods of use thereof
A dna vaccine suitable for eliciting an immune response against cancer cells comprises a dna construct operably encoding a cancer-associated inhibitor of apoptosis-family protein and an immunoactive gene product, such as a cytokine or a ligand for a natural killer cell surface receptor, in a pharmaceutically acceptable carrier. A preferred cytokine is ccl21.
10/30/14
20140322230
Induction of mucosal tolerance to antigens
The present invention relates to the induction of tolerance to antigens, by mucosal, preferably oral delivery of the antigen in combination with an immunomodulating compound producing micro-organism. More specifically, the invention relates to the induction of foxp3+ and/or il-10 and/or tgf-β producing regulatory t-cells, capable of suppressing undesired immune responses toward an antigen, by oral delivery of said antigen in combination with an immunosuppressing cytokine secreting micro-organism..
10/23/14
20140316109
Activated collagen scaffold materials and their special fused active restoration factors
Provided are activated collagen scaffold materials as well as their special fused active restoration factors useful for promoting tissue repair, such as bone damage repair or nerve injury repair. The special fused active restoration factors are fusion proteins comprising a collagen-binding domain (cbd) at n-/c-terminus of cytokines, wherein the collagen-binding domain is a polypeptide consisting of 7-27 amino acid residues with a conservative sequence shown in seq id no:12 at n-terminus.
10/23/14
20140315253
Activated collagen scaffold materials and their special fused active restoration factors
Provided are activated collagen scaffold materials as well as their special fused active restoration factors useful for promoting tissue repair, such as bone damage repair or nerve injury repair. The special fused active restoration factors are fusion proteins comprising a collagen-binding domain (cbd) at n-/c-terminus of cytokines, wherein the collagen-binding domain is a polypeptide consisting of 7-27 amino acid residues with a conservative sequence shown in seq id no:4 at n-terminus.
10/23/14
20140314872
Methods of use of culture supernatant obtained from mesenchymal stem cells from dogs and cats for treatment of organ dysfunction
A method of treatment of organ dysfunction using a supernatant containing molecules, cytokines and vesicles secreted from mesenchymal stem cells (msc) from animals is provided. The msc are cultured, and then centrifuged to separate them from the desired supernatant containing the molecules and vesicles that may be used for treatment.
10/23/14
20140314710
Il-12 p40 monomer, monoclonal antibody against p40 homodimer and the combination of the two for autoimmune disease treatment
A novel approach to discover new drugs against ms and other autoimmune diseases is disclosed. The p40 family of cytokines has four members which include interleukin-12 (il-12), the p40 monomer (p40), the p40 homodimer (p402), and the il-23.
10/23/14
20140311482
Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
The disclosure describes an aerosolizer with (i) means sized for intranasal or paranasal insertion that produces an aerosol from a material for delivery in close proximity to the upper airways, and (ii) the material comprising one or more proinflammatory cytokine inhibitor(s).. .
10/16/14
20140308747
Ex vivo expansion of human hematopoietic stem cells
Methods and kits for expanding the number of hematopoietic stem cells are provided. The methods comprise incubating cells in medium comprising isolated igfbp-2 and an angiopoietin-like protein (angptl).
10/16/14
20140308244
Combination therapy for treatment of inflammatory demyelinating disease
Provided herein include combination therapies for the treatment of neurological inflammatory diseases, such as, for example, demyelinating autoimmune diseases, such as multiple sclerosis and neuromyelitis optica, etc. In various aspects and embodiments, the methods may include administering to a patient an effective dose of an inhibitor of an angiotensin-converting enzyme (ace) in combination with one or more second compounds, in one aspect, provided is a method of treating a demyelinating autoimmune disease (such as multiple sclerosis) that includes administering to a patient an effective dose of an inhibitor of an angiotensin-converting enzyme (ace) in combination with one or more compounds selected from the group consisting of a cytokine, a vitamin b, dimethyl fumarate (dmf, also referred to as bg-12) and fingolimod (gilenya)..
10/16/14
20140308239
Chimeric cytokine formulations for ocular delivery
Featured herein are vehicle formulations and formulations containing a chimeric cytokine designed for e.g., ocular delivery.. .
10/09/14
20140302070
Novel pd1 isoforms, and uses thereof for potentiating immune responses
In one embodiment, the present invention provides a new isoform of human pd1 (Δ42pd1) that contains a 42-nucleotide in-frame deletion located at exon 2 domain. Δ42pd1 does not engage pd-l1/pd-l2, and can induce the production of pro-inflammatory cytokines in one embodiment, Δ42pd1 can be used as an intramolecular adjuvant to develop a fusion dna vaccine for enhancing antigen-specific cd8+ t cell immunity and for prevention of pathogenic infection and/or cancer.
10/09/14
20140301985
Method of treating pancreatic and liver conditions by endoscopic-mediated (or laparoscopic-mediated) transplantation of stem cells into/onto bile duct walls of particular regions of the biliary tree
A method of repairing diseased or dysfunctional pancreas or liver is provided. The method involves preparation of a suspension of stem cells and/or progenitor cells such as biliary tree stem cells, hepatic stem cells, pancreatic stem cells or their descendants, committed progenitor cells, from healthy tissue of the patient or of the biliary tree of a non-autologous donor and engrafting the cells into the wall of bile ducts near to the organ to be treated.
10/02/14
20140295551
Protein markers associated bone marrow stem cell differentiation into early progentior cells
A novel cytosolic 58 kd phosphoprotein induced during bone marrow stem cell (bm) differentiation into dendritic cells (dc) during in vitro cultivation with the cytokine gm-csf by addition of antisera to an 82 kd bm cell surface protein generating cultivatable dendritic progenitor cells (dp). Genes, methods for preparing them as well as early dp have been provided.
10/02/14
20140294931
Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
Thyroid hormone antagonists and their nanoparticle formulations (nanotetrac™ or nanotriac™) act at a cell surface receptor to block angiogenesis and tumor cell proliferation. The complex anti-angiogenic performs actions on specific cytokines and chemokines.
10/02/14
20140294899
Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
A method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of determining whether the human subject is a glatiramer acetate responder by evaluating a biomarker selected from the group consisting of il-17 concentration, tnf-α concentration, il-2 concentration and ifn-γ concentration, or a combination thereof, in the blood of the human subject and administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the human subject only if the human subject is identified as a glatiramer acetate responder.. .
10/02/14
20140294874
Apoaequorin for reducing neuronal injury due to ischemia
The present invention provides apoaequorin-based compositions and methods for preconditioning neurons in a subject to reduce neuronal injury due to brain ischemia. Methods include the step of administering apoaequorin to neurons in a subject, wherein the apoaequorin initiates a change in cytokine expression levels resulting in a reduction of neuronal injury due to brain ischemia as compared to neurons not administered the apoaequorin.
10/02/14
20140294817
Polypeptides comprising fc fragments of immunoglobulin g (igg) and methods of using the same
Polypeptides comprising at least a first and second fc fragment of igg that can be used to induce a stimulated cell to produce the anti-inflammatory cytokine interleukin-10 and methods of using the same are disclosed herein.. .
10/02/14
20140294758
Light chain immunoglobulin fusion proteins and methods of use thereof
Provided are recombinant antibodies comprising one or more peptides fused to the c-terminus of the light chain constant region. Recombinant immunocytokines comprising a cytokine fused to the c-terminus of the light chain constant region are described and shown to be surprisingly active..
09/25/14
20140288661
Bone tissue engineering by ex vivo stem cells ongrowth into three-dimensional trabecular metal
Adult autologous stem cells cultured on a porous, three-dimensional tissue scaffold-implant for bone regeneration by the use of a hyaluronan and/or dexamethasone to accelerate bone healing alone or in combination with recombinant growth factors or transfected osteogenic genes. The scaffold-implant may be machined into a custom-shaped three-dimensional cell culture system for support of cell growth, reservoir for peptides, recombinant growth factors, cytokines and antineoplastic drugs in the presence of a hyaluronan and/or dexamethasone alone or in combination with growth factors or transfected osteogenic genes, to be assembled ex vivo in a tissue incubator for implantation into bone tissue..
09/25/14
20140288545
Methods for bilateral renal neuromodulation
Methods and apparatus are provided for bilateral renal neuromodulation, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.
09/25/14
20140288531
Methods for bilateral renal neuromodulation
Methods and apparatus are provided for bilateral renal neuromodulation, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.
09/25/14
20140286988
Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom
1h-imidazo[4,5-c]quinolin-4-amines substituted at the 1-position with a substituent bearing a hydrazinobenzamide or hydrazinonicotinamide, a salt thereof, or a protected hydrazinobenzamide or hydrazinonicotinamide and conjugates made from such compounds are disclosed. Pharmaceutical compositions containing the compound or the conjugate, methods of making a conjugate, and methods of use of the compounds or conjugates as immunomodulators for inducing cytokine biosynthesis in an animal and for vaccinating an animal are also disclosed..
09/25/14
20140286956
Modulating inflammasome activity and inflammation in the central nervous system
Compositions and methods for reducing inflammation in the central nervous system (cns) of a mammal that has been subjected to a stroke, traumatic injury to the cns such as traumatic brain injury (tbi), spinal cord injury (sci), or having an autoimmune or cns disease have been developed. The compositions and methods described herein include antibodies that specifically bind to at least one component (e.g., asc, nalp1) in a mammalian inflammasome (e.g., the nalp1 inflammasome) and have use as treatments for sci, tbi, stroke, and autoimmune and cns diseases in a mammal.
09/18/14
20140275497
Methods for making cytokine compositions from tissues using non-centrifugal methods
Apparatus and methods for generating a solution rich in interleukin-1 receptor antagonist from a tissue comprising cytokine-producing cells. The apparatus can include a filter used with a separation system.
09/18/14
20140275279
Cysteamine in the treatment of fibrotic disease
Fibrotic diseases are characterized by the replacement of healthy tissue with scar tissue and extracellular matrix in response to tissue damage. Here we describe the reduction of extracellular matrix (ecm) deposition, interstitial fibroblasts, interstitial volume, expression of collagen i mrna and protein, expression of profibrotic cytokines and macrophage infiltration by cysteamine treatment..
09/18/14
20140275271
Novel modified curcumins and their uses
Wherein α, β, a, b, and r1-r4 are defined herein. This invention also provides pharmaceutical compositions comprising the above compounds, a method of accelerating the healing of a wound, a method of inhibiting the activity and/or levels of a matrix metalloproteinase (mmp), a method of inhibiting the production of a cytokine in a population of cells, a method of inhibiting the production of a growth factor in a population of cells, and a method of inhibiting nfκ-b activation in a population of cells..
09/18/14
20140275237
Beraprost isomer as an agent for the treatment of viral infection
In various embodiments the use of single isomer of beraprost as a therapeutic for the treatment of viral disease and other pathologies associated with the induction of a cytokine storm, such as influenza a viruses and the sars-causing coronvirus and mutations thereof is provided.. .
09/18/14
20140274895
Methods and non-immunogenic compositions for treating inflammatory disorders
Methods for making non-immunogenic anti-inflammatory cytokine compositions, comprising (a) obtaining a liquid comprising cytokine producing cells from a mammalian donor; (b) contacting the liquid with a solid extraction material to generate a composition rich in interleukin-1 receptor antagonist; and performing one or both of (i) removing cells from the composition and (ii) freezing the composition. The compositions comprise two or more of il1-ra, stnf-r1, stnf-rii, igf-i, egf, hgf, pdgf-ab, pdgf-bb, vegf, tgf-β1, and sil-1rii, compositions may also contain white blood cells and platelets..
09/18/14
20140274894
Methods for making cytokine compositions from tissues using non-centrifugal methods
Non-centrifugal methods for generating a solution rich in interleukin-1 receptor antagonist from a tissue comprising cytokine-producing cells. The solution rich in il-1ra can also include at least one of stnf-ri, stnf-rii, igf-i, egf, hgf, pdgf-ab, pdgf-bb, vegf, tgf-β1, and sil-1 rii..
09/18/14
20140271773
Medical device
The invention is directed to an improved medical device. In particular, the invention is directed to an improved medical device having a coating comprising novel cellular factor-containing solution compositions (referred to herein as cfs compositions), such cfs compositions including conditioned medium compositions obtained from culturing extraembryonic cytokine secreting cells (ecs cells), including amnion-derived cellular cytokine solution (referred to herein as accs) obtained from culturing amnion-derived multipotent progenitor (amp) cells, dispersed in a polymeric coating material..
09/18/14
20140271725
Small molecule enhancer for dendritic cell cancer vaccines
Disclosed is a method of treating cancer, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound that inhibits a plurality of mammalian dipeptidyl peptidase (dpp) iv activity and/or structural homologues thereof (dash) serine proteases. Also disclosed is a method of (a) increasing antitumor immunity, (b) stimulating or enhancing an immune response, (c) treating a condition characterized by abnormal cell proliferation, (d) increasing cytokine and/or chemokine production, or (e) stimulating or enhancing production of t-cells, in a mammal, comprising administering to a mammal in need thereof an effective amount of a compound that inhibits a plurality of mammalian dash serine proteases.
09/18/14
20140271684
Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
The present invention relates to a method of enhancing the anti-tumor response in a mammal. More particularly, the invention is concerned with combinations comprising a cytokine-secreting cell and an anti-pd-1 antibody, and methods of administering the combination for enhanced immune response to tumor cells in a patient with a cancer..
09/18/14
20140271652
Immunologically active polypeptide
Disclosed are immunomodulatory polypeptides that elicit an unusual induced cytokine profile, compositions comprising such polypeptides, compositions comprising antibodies that specifically bind to such polypeptides, and methods of using the same, including in cancer treatment, in the treatment of autoimmune diseases, in organ transplantation and for reducing graft rejection, for promoting fertility, and for identifying a neutrophil subset and/or other cellular subset including by flow cytometry. Pharmaceutical compositions and kits, and treatment methods are also disclosed..
09/18/14
20140271580
Immunoprotective primary mesenchymal stem cells and methods
Immunoprotective primary mesenchymal stems cells (ip-msc) which episomally express multiple immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The ip-msc express two or more (e.g., 2 to about 100) immunoreactive polypeptides (e.g., full antibodies, single-chain antibodies (scfv), fab or f(ab)2 antibody fragments, diabodies, tribodies, and the like), and optionally one or more other immunomodulating polypeptides, e.g., a cytokine such as an interleukin (e.g., il-2, il-4, il-6, il-7, il-9, and il-12), an interferon (e.g., ifnα, ifnβ, or ifnω), and the like, which can enhance the effectiveness of the immunoreactive polypeptides..
09/18/14
20140271554
Reducing proinflammatory response
The present disclosure provides a method for suppressing a proinflammatory response by administering a composition comprising peptides selected from a casein hydrolysate. Such a composition may reduce the levels of proinflammatory cytokines and may be a treatment for inflammatory disease, especially type 1 diabetes.
09/18/14
20140271553
Nutritional compositions containing a peptide component with anti-inflammatory properties and uses thereof
The present disclosure relates to nutritional compositions comprising a protein equivalent source, wherein 20% to 80% of the protein equivalent source includes a peptide component comprising seq id no 4, seq id no 13, seq id no 17, seq id no 21, seq id no 24, seq id no 30, seq id no 31, seq id no 32, seq id no 51, seq id no 57, seq id no 60, and seq id no 63, and 20% to 80% of the protein equivalent source comprises an intact protein, a partially hydrolyzed protein, or combinations thereof. The disclosure further relates to methods of reducing the inflammatory response and/or production of proinflammatory cytokines, i.e.
09/18/14
20140271539
Novel use of members of il-10 cytokine family
The invention relates to a novel use of the members of the il-10 cytokine family in wound healing. Particularly, the invention relates to the use of the member of the il-10 cytokine family in the promotion of the proliferation and the migration of keratinocyte cells in wound healing..


Popular terms: [SEARCH]

Cytokine topics: Antibodies, Inflammation, Specificity, Immunotherapy, Major Histocompatibility Complex, Compatibility, Combination Therapy, Histocompatibility, Immune Response, Monoclonal Antibody, Stimulator, Therapeutics, Immunostimulator, Monoclonal, Proinflammatory

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Cytokine for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cytokine with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         



Key IP Translations - Patent Translations



0.7026

3318

3 - 0 - 75